Morrell Eric D, O'Mahony D Shane, Glavan Bradford J, Harju-Baker Susanna, Nguyen Catherine, Gunderson Scott, Abrahamson Aaron, Radella Frank, Rona Gail, Black R Anthony, Wurfel Mark M
1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and.
2 Biomedical Informatics Core of the Institute of Translational Health Sciences, University of Washington, Seattle, Washington.
Am J Respir Cell Mol Biol. 2018 Jan;58(1):117-125. doi: 10.1165/rcmb.2017-0030OC.
Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) regulates numerous intracellular signaling pathways involved in inflammation and apoptosis. We hypothesized that genetic variation in MAP3K1 might be associated with outcomes in patients with acute respiratory distress syndrome (ARDS), and that these variants would alter MAP3K1-mediated changes in inflammation and transcriptional regulation. To test this hypothesis, we genotyped single-nucleotide polymorphisms covering linkage disequilibrium bins in MAP3K1 in 306 subjects with ARDS from the ARDSNet FACTT (Fluid and Catheter Treatment Trial) study, and tested for associations between MAP3K1 single-nucleotide polymorphisms and ventilator-free days (VFDs) and mortality. We then validated these associations in a separate cohort of 241 patients with ARDS from Harborview Medical Center (Seattle, WA). We found the variant allele of rs832582 (MAP3K1) was significantly associated with decreased VFDs using multivariate linear regression (-6.1 d, false discovery rate = 0.06) in the FACTT cohort. In the Harborview Medical Center cohort, subjects homozygous for MAP3K1 also had decreased VFDs (-15.1 d, false discovery rate < 0.01), and increased 28-day mortality (all subjects homozygous for the rare allele died). In whole blood stimulated with various innate immune agonists ex vivo, MAP3K1 was associated with increased IL-1β, IL-6, IL-8, monocyte chemoattractant protein 1, and TNF-α production. Transcriptome analysis of whole blood stimulated with Toll-like receptor 4 agonist ex vivo demonstrated enrichment of inflammatory gene sets in subjects homozygous for MAP3K1. Our findings show a robust association between the variant allele of rs832582 (MAP3K1) and decreased VFDs in patients with ARDS and suggest that this variant may predispose individuals to a greater inflammatory response.
丝裂原活化蛋白激酶激酶激酶1(MAP3K1)调节许多参与炎症和细胞凋亡的细胞内信号通路。我们假设MAP3K1的基因变异可能与急性呼吸窘迫综合征(ARDS)患者的预后相关,并且这些变异会改变MAP3K1介导的炎症和转录调控变化。为了验证这一假设,我们对急性呼吸窘迫综合征网络FACTT(液体与导管治疗试验)研究中306例ARDS患者的MAP3K1中涵盖连锁不平衡区域的单核苷酸多态性进行了基因分型,并测试了MAP3K1单核苷酸多态性与无呼吸机天数(VFDs)和死亡率之间的关联。然后,我们在来自哈博维尤医疗中心(华盛顿州西雅图)的另一组241例ARDS患者中验证了这些关联。我们发现,使用多变量线性回归分析,在FACTT队列中,rs832582(MAP3K1)的变异等位基因与VFDs减少显著相关(-6.1天,错误发现率=0.06)。在哈博维尤医疗中心队列中,MAP3K1纯合子受试者的VFDs也减少了(-15.1天,错误发现率<0.01),并且28天死亡率增加(所有罕见等位基因纯合子受试者均死亡)。在体外使用各种天然免疫激动剂刺激的全血中,MAP3K1与白细胞介素-1β、白细胞介素-6、白细胞介素-8、单核细胞趋化蛋白1和肿瘤坏死因子-α的产生增加相关。体外使用Toll样受体4激动剂刺激全血的转录组分析表明,MAP3K1纯合子受试者中炎症基因集富集。我们的研究结果表明,rs832582(MAP3K1)的变异等位基因与ARDS患者的VFDs减少之间存在密切关联,并表明该变异可能使个体更容易产生更强的炎症反应。